JOURNAL ARTICLE

309 Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest.

  • Published In: British Journal of Dermatology, 2023, v. 188. P. ii6 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Reich, Kristian; Simpson, Eric; Langley, Richard; Warren, Richard B; Costanzo, Antonio; Hidehisa Saeki; Almgren, Peter; Gjerum, Le; Carlsson, Anna; Gooderham, Melinda; Pinter, Andreas; De Bruin Weller, Marjolein; Blauvelt, Andrew 3 of 3

Abstract

This article focuses on the long-term safety profile of tralokinumab, a monoclonal antibody targeting interleukin-13, in adults with moderate-to-severe atopic dermatitis (AD). An interim analysis from the ongoing ECZTEND open-label extension trial, involving 1,442 patients treated for up to 42 months, showed that tralokinumab was generally well tolerated, with adverse event rates similar to or lower than those observed in earlier placebo-controlled trials. Adverse events of special interest, including eye disorders such as conjunctivitis, skin infections requiring systemic treatment, eczema herpeticum, and malignancies, occurred at low or decreasing rates over time. These findings support the sustained benefit-risk profile of tralokinumab for long-term management of moderate-to-severe AD.

Additional Information

  • Source:British Journal of Dermatology. 2023/02, Vol. 188, pii6
  • Document Type:Article
  • Subject Area:Consumer Health
  • Publication Date:2023
  • ISSN:0007-0963
  • DOI:10.1093/bjd/ljac140.009
  • Accession Number:162274702
  • Copyright Statement:Copyright of British Journal of Dermatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.